The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence

Purpose To predict biochemical recurrence respecting the natural course of pT2 prostate cancer with positive surgical margin (R1) and no adjuvant/neoadjuvant therapy. Methods A multicenter data analysis of 956 patients with pT2R1N0/Nx tumors was performed. Patients underwent radical prostatectomy be...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:World journal of urology 2015-07, Vol.33 (7), p.973-979
Hauptverfasser: Karl, A., Buchner, A., Tympner, C., Kirchner, T., Ganswindt, U., Belka, C., Ganzer, R., Burger, M., Eder, F., Hofstädter, F., Schilling, D., Sievert, K., Stenzl, A., Scharpf, M., Fend, F., vom Dorp, F., Rübben, H., Schmid, K., Porres-Knoblauch, D., Heidenreich, A., Hangarter, B., Knüchel-Clarke, R., Rogenhofer, M., Wullich, B., Hartmann, A., Comploj, E., Pycha, A., Hanspeter, E., Pehrke, D., Sauter, G., Graefen, M., Stief, C., Haese, A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 979
container_issue 7
container_start_page 973
container_title World journal of urology
container_volume 33
creator Karl, A.
Buchner, A.
Tympner, C.
Kirchner, T.
Ganswindt, U.
Belka, C.
Ganzer, R.
Burger, M.
Eder, F.
Hofstädter, F.
Schilling, D.
Sievert, K.
Stenzl, A.
Scharpf, M.
Fend, F.
vom Dorp, F.
Rübben, H.
Schmid, K.
Porres-Knoblauch, D.
Heidenreich, A.
Hangarter, B.
Knüchel-Clarke, R.
Rogenhofer, M.
Wullich, B.
Hartmann, A.
Comploj, E.
Pycha, A.
Hanspeter, E.
Pehrke, D.
Sauter, G.
Graefen, M.
Stief, C.
Haese, A.
description Purpose To predict biochemical recurrence respecting the natural course of pT2 prostate cancer with positive surgical margin (R1) and no adjuvant/neoadjuvant therapy. Methods A multicenter data analysis of 956 patients with pT2R1N0/Nx tumors was performed. Patients underwent radical prostatectomy between 1994 and 2009. No patients received neoadjuvant or adjuvant therapy. All prostate specimens were re-evaluated according to a well-defined protocol. The association of pathological and clinical features, in regard to BCR, was calculated using various statistical tests. Results With a mean follow-up of 48 months, BCR was found in 25.4 %. In univariate analysis, multiple parameters such as tumor volume, PSA, Gleason at positive margin were significantly associated with BCR. However, in multivariate analysis, Gleason score (GS) of the prostatectomy specimen was the only significant parameter for BCR. Median time to recurrence for GS ≤ 6 was not reached; 5-year BCR-free survival was 82 %; and they were 127 months and 72 % for GS 3+4, 56 months and 54 % for GS 4 + 3, and 27 months and 32 % for GS 8–10. The retrospective approach is a limitation of our study. Conclusions Our study provides data on the BCR in pT2R1-PCa without adjuvant/neoadjuvant therapy and thus a rationale for an individual’s risk stratification. The data support patients and physicians in estimating the individual risk and timing of BCR and thus serve to personalize the management in pT2R1-PCa.
doi_str_mv 10.1007/s00345-015-1510-y
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1691594750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3759903531</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-a82239e2552518fd40854e7b8be5c2d87a32c9fa4fa52b79767a69a778c2ab913</originalsourceid><addsrcrecordid>eNp1kc1OAyEUhYnR2Fp9ADeGxI2bUWBgAHem8S9p4qauCUPvtDTtTIUZTd9e6lRjTFxBcr9z4J6D0Dkl15QQeRMJybnICBUZFZRk2wM0pDzPMyVZcYiGRDKeca3yATqJcUkIlQURx2jARKEYJXqIltMF4Nq2XbAr7JouRMBNhTdThjehia1tATtbOwj4w7cLvGmib_074NiFuXdJtLbpUt8mHGbetb6e49I3bgHrr3EA14UAyeEUHVV2FeFsf47Q68P9dPyUTV4en8d3k8xxztrMKsZyDUwIJqiqZpwowUGWqgTh2ExJmzOnK8srK1gptSykLbSVUjlmS03zEbrqfdMCbx3E1qx9dLBa2RqaLhpaaCo0l4Ik9PIPukwR1Ol3O0ozmguqE0V7yqVEYoDKbIJPa28NJWZXhOmLMKkIsyvCbJPmYu_clWuY_Si-k08A64GYRvUcwq-n_3X9BHl1lBQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1699213519</pqid></control><display><type>article</type><title>The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Karl, A. ; Buchner, A. ; Tympner, C. ; Kirchner, T. ; Ganswindt, U. ; Belka, C. ; Ganzer, R. ; Burger, M. ; Eder, F. ; Hofstädter, F. ; Schilling, D. ; Sievert, K. ; Stenzl, A. ; Scharpf, M. ; Fend, F. ; vom Dorp, F. ; Rübben, H. ; Schmid, K. ; Porres-Knoblauch, D. ; Heidenreich, A. ; Hangarter, B. ; Knüchel-Clarke, R. ; Rogenhofer, M. ; Wullich, B. ; Hartmann, A. ; Comploj, E. ; Pycha, A. ; Hanspeter, E. ; Pehrke, D. ; Sauter, G. ; Graefen, M. ; Stief, C. ; Haese, A.</creator><creatorcontrib>Karl, A. ; Buchner, A. ; Tympner, C. ; Kirchner, T. ; Ganswindt, U. ; Belka, C. ; Ganzer, R. ; Burger, M. ; Eder, F. ; Hofstädter, F. ; Schilling, D. ; Sievert, K. ; Stenzl, A. ; Scharpf, M. ; Fend, F. ; vom Dorp, F. ; Rübben, H. ; Schmid, K. ; Porres-Knoblauch, D. ; Heidenreich, A. ; Hangarter, B. ; Knüchel-Clarke, R. ; Rogenhofer, M. ; Wullich, B. ; Hartmann, A. ; Comploj, E. ; Pycha, A. ; Hanspeter, E. ; Pehrke, D. ; Sauter, G. ; Graefen, M. ; Stief, C. ; Haese, A.</creatorcontrib><description>Purpose To predict biochemical recurrence respecting the natural course of pT2 prostate cancer with positive surgical margin (R1) and no adjuvant/neoadjuvant therapy. Methods A multicenter data analysis of 956 patients with pT2R1N0/Nx tumors was performed. Patients underwent radical prostatectomy between 1994 and 2009. No patients received neoadjuvant or adjuvant therapy. All prostate specimens were re-evaluated according to a well-defined protocol. The association of pathological and clinical features, in regard to BCR, was calculated using various statistical tests. Results With a mean follow-up of 48 months, BCR was found in 25.4 %. In univariate analysis, multiple parameters such as tumor volume, PSA, Gleason at positive margin were significantly associated with BCR. However, in multivariate analysis, Gleason score (GS) of the prostatectomy specimen was the only significant parameter for BCR. Median time to recurrence for GS ≤ 6 was not reached; 5-year BCR-free survival was 82 %; and they were 127 months and 72 % for GS 3+4, 56 months and 54 % for GS 4 + 3, and 27 months and 32 % for GS 8–10. The retrospective approach is a limitation of our study. Conclusions Our study provides data on the BCR in pT2R1-PCa without adjuvant/neoadjuvant therapy and thus a rationale for an individual’s risk stratification. The data support patients and physicians in estimating the individual risk and timing of BCR and thus serve to personalize the management in pT2R1-PCa.</description><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/s00345-015-1510-y</identifier><identifier>PMID: 25682109</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Humans ; Kallikreins - blood ; Male ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Staging ; Neoplasm, Residual ; Nephrology ; Oncology ; Original Article ; Prostate-Specific Antigen - blood ; Prostatectomy ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; Retrospective Studies ; Treatment Outcome ; Urology</subject><ispartof>World journal of urology, 2015-07, Vol.33 (7), p.973-979</ispartof><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-a82239e2552518fd40854e7b8be5c2d87a32c9fa4fa52b79767a69a778c2ab913</citedby><cites>FETCH-LOGICAL-c442t-a82239e2552518fd40854e7b8be5c2d87a32c9fa4fa52b79767a69a778c2ab913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00345-015-1510-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00345-015-1510-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25682109$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karl, A.</creatorcontrib><creatorcontrib>Buchner, A.</creatorcontrib><creatorcontrib>Tympner, C.</creatorcontrib><creatorcontrib>Kirchner, T.</creatorcontrib><creatorcontrib>Ganswindt, U.</creatorcontrib><creatorcontrib>Belka, C.</creatorcontrib><creatorcontrib>Ganzer, R.</creatorcontrib><creatorcontrib>Burger, M.</creatorcontrib><creatorcontrib>Eder, F.</creatorcontrib><creatorcontrib>Hofstädter, F.</creatorcontrib><creatorcontrib>Schilling, D.</creatorcontrib><creatorcontrib>Sievert, K.</creatorcontrib><creatorcontrib>Stenzl, A.</creatorcontrib><creatorcontrib>Scharpf, M.</creatorcontrib><creatorcontrib>Fend, F.</creatorcontrib><creatorcontrib>vom Dorp, F.</creatorcontrib><creatorcontrib>Rübben, H.</creatorcontrib><creatorcontrib>Schmid, K.</creatorcontrib><creatorcontrib>Porres-Knoblauch, D.</creatorcontrib><creatorcontrib>Heidenreich, A.</creatorcontrib><creatorcontrib>Hangarter, B.</creatorcontrib><creatorcontrib>Knüchel-Clarke, R.</creatorcontrib><creatorcontrib>Rogenhofer, M.</creatorcontrib><creatorcontrib>Wullich, B.</creatorcontrib><creatorcontrib>Hartmann, A.</creatorcontrib><creatorcontrib>Comploj, E.</creatorcontrib><creatorcontrib>Pycha, A.</creatorcontrib><creatorcontrib>Hanspeter, E.</creatorcontrib><creatorcontrib>Pehrke, D.</creatorcontrib><creatorcontrib>Sauter, G.</creatorcontrib><creatorcontrib>Graefen, M.</creatorcontrib><creatorcontrib>Stief, C.</creatorcontrib><creatorcontrib>Haese, A.</creatorcontrib><title>The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><addtitle>World J Urol</addtitle><description>Purpose To predict biochemical recurrence respecting the natural course of pT2 prostate cancer with positive surgical margin (R1) and no adjuvant/neoadjuvant therapy. Methods A multicenter data analysis of 956 patients with pT2R1N0/Nx tumors was performed. Patients underwent radical prostatectomy between 1994 and 2009. No patients received neoadjuvant or adjuvant therapy. All prostate specimens were re-evaluated according to a well-defined protocol. The association of pathological and clinical features, in regard to BCR, was calculated using various statistical tests. Results With a mean follow-up of 48 months, BCR was found in 25.4 %. In univariate analysis, multiple parameters such as tumor volume, PSA, Gleason at positive margin were significantly associated with BCR. However, in multivariate analysis, Gleason score (GS) of the prostatectomy specimen was the only significant parameter for BCR. Median time to recurrence for GS ≤ 6 was not reached; 5-year BCR-free survival was 82 %; and they were 127 months and 72 % for GS 3+4, 56 months and 54 % for GS 4 + 3, and 27 months and 32 % for GS 8–10. The retrospective approach is a limitation of our study. Conclusions Our study provides data on the BCR in pT2R1-PCa without adjuvant/neoadjuvant therapy and thus a rationale for an individual’s risk stratification. The data support patients and physicians in estimating the individual risk and timing of BCR and thus serve to personalize the management in pT2R1-PCa.</description><subject>Adult</subject><subject>Aged</subject><subject>Humans</subject><subject>Kallikreins - blood</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Staging</subject><subject>Neoplasm, Residual</subject><subject>Nephrology</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatectomy</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Urology</subject><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc1OAyEUhYnR2Fp9ADeGxI2bUWBgAHem8S9p4qauCUPvtDTtTIUZTd9e6lRjTFxBcr9z4J6D0Dkl15QQeRMJybnICBUZFZRk2wM0pDzPMyVZcYiGRDKeca3yATqJcUkIlQURx2jARKEYJXqIltMF4Nq2XbAr7JouRMBNhTdThjehia1tATtbOwj4w7cLvGmib_074NiFuXdJtLbpUt8mHGbetb6e49I3bgHrr3EA14UAyeEUHVV2FeFsf47Q68P9dPyUTV4en8d3k8xxztrMKsZyDUwIJqiqZpwowUGWqgTh2ExJmzOnK8srK1gptSykLbSVUjlmS03zEbrqfdMCbx3E1qx9dLBa2RqaLhpaaCo0l4Ik9PIPukwR1Ol3O0ozmguqE0V7yqVEYoDKbIJPa28NJWZXhOmLMKkIsyvCbJPmYu_clWuY_Si-k08A64GYRvUcwq-n_3X9BHl1lBQ</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Karl, A.</creator><creator>Buchner, A.</creator><creator>Tympner, C.</creator><creator>Kirchner, T.</creator><creator>Ganswindt, U.</creator><creator>Belka, C.</creator><creator>Ganzer, R.</creator><creator>Burger, M.</creator><creator>Eder, F.</creator><creator>Hofstädter, F.</creator><creator>Schilling, D.</creator><creator>Sievert, K.</creator><creator>Stenzl, A.</creator><creator>Scharpf, M.</creator><creator>Fend, F.</creator><creator>vom Dorp, F.</creator><creator>Rübben, H.</creator><creator>Schmid, K.</creator><creator>Porres-Knoblauch, D.</creator><creator>Heidenreich, A.</creator><creator>Hangarter, B.</creator><creator>Knüchel-Clarke, R.</creator><creator>Rogenhofer, M.</creator><creator>Wullich, B.</creator><creator>Hartmann, A.</creator><creator>Comploj, E.</creator><creator>Pycha, A.</creator><creator>Hanspeter, E.</creator><creator>Pehrke, D.</creator><creator>Sauter, G.</creator><creator>Graefen, M.</creator><creator>Stief, C.</creator><creator>Haese, A.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150701</creationdate><title>The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence</title><author>Karl, A. ; Buchner, A. ; Tympner, C. ; Kirchner, T. ; Ganswindt, U. ; Belka, C. ; Ganzer, R. ; Burger, M. ; Eder, F. ; Hofstädter, F. ; Schilling, D. ; Sievert, K. ; Stenzl, A. ; Scharpf, M. ; Fend, F. ; vom Dorp, F. ; Rübben, H. ; Schmid, K. ; Porres-Knoblauch, D. ; Heidenreich, A. ; Hangarter, B. ; Knüchel-Clarke, R. ; Rogenhofer, M. ; Wullich, B. ; Hartmann, A. ; Comploj, E. ; Pycha, A. ; Hanspeter, E. ; Pehrke, D. ; Sauter, G. ; Graefen, M. ; Stief, C. ; Haese, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-a82239e2552518fd40854e7b8be5c2d87a32c9fa4fa52b79767a69a778c2ab913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Humans</topic><topic>Kallikreins - blood</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Staging</topic><topic>Neoplasm, Residual</topic><topic>Nephrology</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatectomy</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karl, A.</creatorcontrib><creatorcontrib>Buchner, A.</creatorcontrib><creatorcontrib>Tympner, C.</creatorcontrib><creatorcontrib>Kirchner, T.</creatorcontrib><creatorcontrib>Ganswindt, U.</creatorcontrib><creatorcontrib>Belka, C.</creatorcontrib><creatorcontrib>Ganzer, R.</creatorcontrib><creatorcontrib>Burger, M.</creatorcontrib><creatorcontrib>Eder, F.</creatorcontrib><creatorcontrib>Hofstädter, F.</creatorcontrib><creatorcontrib>Schilling, D.</creatorcontrib><creatorcontrib>Sievert, K.</creatorcontrib><creatorcontrib>Stenzl, A.</creatorcontrib><creatorcontrib>Scharpf, M.</creatorcontrib><creatorcontrib>Fend, F.</creatorcontrib><creatorcontrib>vom Dorp, F.</creatorcontrib><creatorcontrib>Rübben, H.</creatorcontrib><creatorcontrib>Schmid, K.</creatorcontrib><creatorcontrib>Porres-Knoblauch, D.</creatorcontrib><creatorcontrib>Heidenreich, A.</creatorcontrib><creatorcontrib>Hangarter, B.</creatorcontrib><creatorcontrib>Knüchel-Clarke, R.</creatorcontrib><creatorcontrib>Rogenhofer, M.</creatorcontrib><creatorcontrib>Wullich, B.</creatorcontrib><creatorcontrib>Hartmann, A.</creatorcontrib><creatorcontrib>Comploj, E.</creatorcontrib><creatorcontrib>Pycha, A.</creatorcontrib><creatorcontrib>Hanspeter, E.</creatorcontrib><creatorcontrib>Pehrke, D.</creatorcontrib><creatorcontrib>Sauter, G.</creatorcontrib><creatorcontrib>Graefen, M.</creatorcontrib><creatorcontrib>Stief, C.</creatorcontrib><creatorcontrib>Haese, A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karl, A.</au><au>Buchner, A.</au><au>Tympner, C.</au><au>Kirchner, T.</au><au>Ganswindt, U.</au><au>Belka, C.</au><au>Ganzer, R.</au><au>Burger, M.</au><au>Eder, F.</au><au>Hofstädter, F.</au><au>Schilling, D.</au><au>Sievert, K.</au><au>Stenzl, A.</au><au>Scharpf, M.</au><au>Fend, F.</au><au>vom Dorp, F.</au><au>Rübben, H.</au><au>Schmid, K.</au><au>Porres-Knoblauch, D.</au><au>Heidenreich, A.</au><au>Hangarter, B.</au><au>Knüchel-Clarke, R.</au><au>Rogenhofer, M.</au><au>Wullich, B.</au><au>Hartmann, A.</au><au>Comploj, E.</au><au>Pycha, A.</au><au>Hanspeter, E.</au><au>Pehrke, D.</au><au>Sauter, G.</au><au>Graefen, M.</au><au>Stief, C.</au><au>Haese, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence</atitle><jtitle>World journal of urology</jtitle><stitle>World J Urol</stitle><addtitle>World J Urol</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>33</volume><issue>7</issue><spage>973</spage><epage>979</epage><pages>973-979</pages><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>Purpose To predict biochemical recurrence respecting the natural course of pT2 prostate cancer with positive surgical margin (R1) and no adjuvant/neoadjuvant therapy. Methods A multicenter data analysis of 956 patients with pT2R1N0/Nx tumors was performed. Patients underwent radical prostatectomy between 1994 and 2009. No patients received neoadjuvant or adjuvant therapy. All prostate specimens were re-evaluated according to a well-defined protocol. The association of pathological and clinical features, in regard to BCR, was calculated using various statistical tests. Results With a mean follow-up of 48 months, BCR was found in 25.4 %. In univariate analysis, multiple parameters such as tumor volume, PSA, Gleason at positive margin were significantly associated with BCR. However, in multivariate analysis, Gleason score (GS) of the prostatectomy specimen was the only significant parameter for BCR. Median time to recurrence for GS ≤ 6 was not reached; 5-year BCR-free survival was 82 %; and they were 127 months and 72 % for GS 3+4, 56 months and 54 % for GS 4 + 3, and 27 months and 32 % for GS 8–10. The retrospective approach is a limitation of our study. Conclusions Our study provides data on the BCR in pT2R1-PCa without adjuvant/neoadjuvant therapy and thus a rationale for an individual’s risk stratification. The data support patients and physicians in estimating the individual risk and timing of BCR and thus serve to personalize the management in pT2R1-PCa.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25682109</pmid><doi>10.1007/s00345-015-1510-y</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0724-4983
ispartof World journal of urology, 2015-07, Vol.33 (7), p.973-979
issn 0724-4983
1433-8726
language eng
recordid cdi_proquest_miscellaneous_1691594750
source MEDLINE; SpringerLink Journals
subjects Adult
Aged
Humans
Kallikreins - blood
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Grading
Neoplasm Recurrence, Local - blood
Neoplasm Recurrence, Local - diagnosis
Neoplasm Staging
Neoplasm, Residual
Nephrology
Oncology
Original Article
Prostate-Specific Antigen - blood
Prostatectomy
Prostatic Neoplasms - blood
Prostatic Neoplasms - pathology
Prostatic Neoplasms - surgery
Retrospective Studies
Treatment Outcome
Urology
title The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T03%3A15%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20natural%20course%20of%20pT2%20prostate%20cancer%20with%20positive%20surgical%20margin:%20predicting%20biochemical%20recurrence&rft.jtitle=World%20journal%20of%20urology&rft.au=Karl,%20A.&rft.date=2015-07-01&rft.volume=33&rft.issue=7&rft.spage=973&rft.epage=979&rft.pages=973-979&rft.issn=0724-4983&rft.eissn=1433-8726&rft_id=info:doi/10.1007/s00345-015-1510-y&rft_dat=%3Cproquest_cross%3E3759903531%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1699213519&rft_id=info:pmid/25682109&rfr_iscdi=true